Rubicon Research Peer Comparison

NSE: RUBICON | BSE: 544578

₹1,548.50

₹13.10 (0.85%)

As on 09-Oct-2026IST

Market cap

₹25,602 Cr

Revenue (TTM)

₹1,936 Cr

P/E Ratio

88.8

P/B Ratio

19.1

Div. Yield

0.1 %

Edit

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Market cap (₹ Cr)	25,602	32,453	26,181	25,872	22,200
Revenue (₹ Cr)	1,936	3,564	9,205	1,462	5,632
Net Profit (₹ Cr)	288.22	414.00	-371.81	387.35	662.35
Net Margin (%)	14.79	11.23	-3.93	26.01	11.75
RoE (%)	29.77	8.38	-3.85	25.18	14.34
Price to Earnings	88.83	79.35	--	66.99	33.52
Price-To-Book	19.07	6.45	3.27	14.99	4.53

Income Statement (₹ Cr)

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Operating Revenue	1,935.80	3,564.00	9,205.28	1,461.80	5,632.31
Total Income	1,948.58	3,686.00	9,449.59	1,489.25	5,638.56
Total Expenditure	1,485.56	2,792.00	8,195.15	919.25	4,354.97
EBITDA	450.24	772.00	1,010.13	542.56	1,277.34
Depreciation	50.83	226.00	857.51	37.68	306.94
EBIT	399.41	546.00	152.62	504.88	970.39
Interest	40.84	217.00	342.73	3.77	111.70
Other Income	12.78	122.00	244.31	27.45	6.25
Exceptional Items	0.00	12.00	-216.88	0.00	15.92
Profit before Tax	371.35	463.00	-162.68	528.56	880.86
Provision for Tax	83.14	49.00	209.13	141.21	218.51
Profit after Tax	288.22	414.00	-371.81	387.35	662.35

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Shareholder's Funds	1,288.82	4,940.00	8,162.62	1,653.56	5,085.00
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	202.03	1,712.00	5,044.14	42.40	542.92
Current Liabilities	835.87	1,622.00	4,758.28	230.82	2,092.03
Total Liabilities	2,326.71	8,578.00	17,723.32	1,983.96	7,682.91

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Non-Current Assets	519.60	5,343.00	10,211.52	1,026.85	3,533.26
Current Assets	1,681.81	2,606.00	7,191.66	881.27	3,767.65
Total Assets	2,326.71	8,578.00	17,723.32	1,983.96	7,682.91
Total Debt*	259.37	2,125.00	5,495.48	26.49	1,338.13
Net Current Assets	845.94	984.00	2,433.38	650.46	1,675.62
Contingent Liabilities	19.09	768.26	95.72	17.25	0.93

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Cash From Operating Activities	205.05	390.00	1,652.60	292.17	793.25
Cash Flow from Investing Activities	-409.72	-241.00	-826.03	-265.94	-773.21
Cash from Financing Activities	283.07	-54.00	-38.98	4.10	379.29
Net Cash Inflow / Outflow	78.39	95.00	787.59	30.33	399.33

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
ROCE (%)	29.22	6.79	1.24	32.42	15.74
ROE (%)	29.77	8.38	-3.85	25.18	14.34
ROA (%)	24.77	4.94	-2.21	21.93	9.48
EBIT Margin (%)	20.63	15.32	1.66	34.54	17.23
Net Margin (%)	14.79	11.23	-3.93	26.01	11.75
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Revenue Growth (%)	46.65	18.37	0.78	40.90	24.83
EBIT Growth (%)	62.13	252.26	-70.53	124.50	40.39
Net Profit Growth (%)	89.49	377.85	-1,383.43	104.15	38.13
EPS Growth (%)	78.60	1,001.33	-484.84	42.32	34.88
Book Value Growth (%)	144.31	13.47	0.33	26.03	27.49

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Price / Earnings	87.46	81.44	-83.67	66.99	30.74
Price / Book Value	19.07	6.45	3.27	14.99	4.53
Dividend Yield (%)	0.10	0.00	0.00	0.08	0.22
EV/EBITDA	56.67	43.93	30.02	47.32	17.68
Market Cap (₹ Cr)	12,753.19	19,071.62	18,108.89	20,944.75	15,391.88

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Debt to Equity	0.11	0.31	0.53	0.02	0.06
Short term debt to equity ratio	0.05	0.09	0.09	0.02	0.20
Current Ratio	2.01	1.61	1.51	3.82	1.80
Quick Ratio	1.14	1.06	0.87	2.82	1.00
Interest Coverage	10.09	3.13	0.53	141.16	8.89

	Rubicon Research	Wockhardt	Piramal Pharma	Acutaas Chemicals	Granules India
Debtors to sales (%)	26.28	16.50	23.44	24.80	16.15
Asset Turnover	1.66	0.43	0.55	0.83	0.81
Receivable days	40.13	58.75	78.20	88.98	33.72
Inventory Days	60.29	75.82	93.30	56.04	54.92
Payable days	232.47	186.21	226.14	99.95	136.11
Cash Conversion Cycle	-132.04	-51.64	-54.64	45.07	-47.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.